Abstract
BackgroundExtracorporeal membrane oxygenation (ECMO) was frequently used to treat patients with severe coronavirus disease-2019 (COVID-19)-associated acute respiratory distress (ARDS) during the initial outbreak. Care of COVID-19 patients evolved markedly during the second part of 2020. Our objective was to compare the characteristics and outcomes of patients who received ECMO for severe COVID-19 ARDS before or after July 1, 2020.MethodsWe included consecutive adults diagnosed with COVID-19 in Paris–Sorbonne University Hospital Network ICUs, who received ECMO for severe ARDS until January 28, 2021. Characteristics and survival probabilities over time were estimated during the first and second waves. Pre-ECMO risk factors predicting 90-day mortality were assessed using multivariate Cox regression.ResultsCharacteristics of the 88 and 71 patients admitted, respectively, before and after July 1, 2020, were comparable except for older age, more frequent use of dexamethasone (18% vs. 82%), high-flow nasal oxygenation (19% vs. 82%) and/or non-invasive ventilation (7% vs. 37%) after July 1. Respective estimated probabilities (95% confidence intervals) of 90-day mortality were 36% (27–47%) and 48% (37–60%) during the first and the second periods. After adjusting for confounders, probability of 90-day mortality was significantly higher for patients treated after July 1 (HR 2.27, 95% CI 1.02–5.07). ECMO-related complications did not differ between study periods.Conclusions90-day mortality of ECMO-supported COVID-19–ARDS patients increased significantly after July 1, 2020, and was no longer comparable to that of non-COVID ECMO-treated patients. Failure of prolonged non-invasive oxygenation strategies before intubation and increased lung damage may partly explain this outcome.
Highlights
Extracorporeal membrane oxygenation (ECMO) was frequently used to treat coronavirus disease-2019 (COVID19) patients with severe acute respiratory distress syndrome (ARDS) during the initial outbreak from January to June 2020 [1,2,3,4]
Patients admitted after July 1 were significantly older, while the numbers and types of failing organs at ECMO cannulation were comparable
Respective before and after High-flow oxygen through a nasal cannula (HFNO) (19% vs. 82%) and/ or noninvasive ventilation (NIV) (7% vs. 37%) use and their durations before
Summary
Extracorporeal membrane oxygenation (ECMO) was frequently used to treat coronavirus disease-2019 (COVID19) patients with severe acute respiratory distress syndrome (ARDS) during the initial outbreak from January to June 2020 [1,2,3,4]. In June 2020, RECOVERY-trial results showed that dexamethasone (6 mg/day for 10 days) significantly reduced mortality compared to usual care for patients receiving either invasive mechanical ventilation or oxygen alone. That dexamethasone regimen was recommended by the World Health Organization and largely prescribed to COVID-19 patients. Extracorporeal membrane oxygenation (ECMO) was frequently used to treat patients with severe coronavirus disease-2019 (COVID-19)-associated acute respiratory distress (ARDS) during the initial outbreak. Our objective was to compare the characteris‐ tics and outcomes of patients who received ECMO for severe COVID-19 ARDS before or after July 1, 2020
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
